Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Generic Core Delivers; Substantial Upside with Lovaza on Horizon - StreetInsider.com

Needham & Company maintains a 'Strong Buy' on Par Pharmaceutical (NYSE: PRX) price target raised from $42 to $48. Analyst, Elliot Wilbur, said, "Even a light launch calendar couldn’t stop PRX from outstripping Street expectations in 1Q12 as top-line ...

Omega-3-acid ethyl esters - Comprehensive patent search - Sacramento Bee

Omega-3-acid ethyl esters innovator: olvay (Omacor); Reliant (Lovaza, Omacor); Pronova (Omacor); Ferrer (Omacor) Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait. Used by the worlds ...

DSM eyes generic omega-3 drug space with €420m ONC buy - Nutra Ingredients USA

DSM board member Stephan Tanda told us the drug route was largely unexplored as ONC does little business in that space, but events were conspiring in its favour as GlaxoSmithKline’s blockbuster lipid regulator, Lovaza, is set to go off patent later this year.

Amarin: Most Undervalued Name In Biotech? - Seekingalpha.com

Lovaza, GlaxoSmithKline's $1b competitor, is shown to increase LDL levels by a median amount of 44.5% per their own label, with only a marginal increase over reducing TG levels versus AMR101. This is an important fact going forward. The ANCHOR data also ...

Fish for the heart - Norwalk Hour

Within the last few years, a new prescription medication has been introduced (LOVAZA) that, along with a low-fat and a low-cholesterol diet, will help to lower very high triglycerides in the blood. Columnist Robert Weiss, a sports podiatrist, was a member ...

Researchers Looking for Drug Candidates Tap into the Final Frontier: The Sea - Genetic Engineering News

In terms of nontoxic drugs from the sea, Dr. Gerwick cited the success of Lovaza, a semisynthetic drug consisting of omega-3 fatty acids purified from fish, then synthetically converted to ethyl esters to allow for easier purifications.

UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Comments From Conference Call - StreetInsider.com

indicated that it is on track to meet full yr guidance of ~$180M; (6) Management remains confident in its Lovaza application/ court case and is ready for a launch." UBS adjusts FY12 EPS estimate from $4.03 to $3.96. For an analyst ratings summary and ...

May 16th's Bio Pharma Catalyst Watch List - Seekingalpha.com

This was erroneous on my behalf as Lipitor is used to mainly treat patients high cholesterol levels while AMR101 is more in line to compete with Lovaza, which also focuses on patients with elevated triglyceride levels. AMR101, if approved, should compete ...